Navigation Links
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date:4/29/2009

nome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Ge
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... ... August 05, 2015 , ... MTI-GlobalStem, ... the launch of an updated corporate identity, including new company name, logo and ... in 2009. The company moved into a new, joint facility in 2014 to ...
(Date:8/4/2015)... (NYSE: BIOA ), a leader in renewable materials ... June 30, 2015. Highlights included: , The Sarnia plant ... final cost of the Sarnia plant is projected to ... end of the estimate communicated at the onset of ... company announced commercial collaborations in two targeted industry segments; ...
(Date:8/4/2015)... According to a new ... Cardiac Biomarker - Market Opportunities, and Forecast, 2014-2020", ... revenue of $2,085.9 million by 2020, registering a ... Troponins (T, I) would continue to dominate the ... sensitivity and specificity.      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:8/4/2015)... ... August 04, 2015 , ... RPS Diagnostics (RPS®) – a ... that Robert A. Gregg, PhD, has joined RPS as Senior Vice President of ... experience and remarkable achievements in the medical device and diagnostics industries. , “Bob ...
Breaking Biology Technology:MTI-GlobalStem Announces Updated Company Identity and Website 2MTI-GlobalStem Announces Updated Company Identity and Website 3BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3
... Dec. 17 Phosphagenics,Limited ("Phosphagenics") (ASX: POH, AIM: ... Phase 1 clinical trial that showed its,delivery technology, ... without causing disruption or irritation of any kind., ... the first company to,commercialize a sustained release oxycodone ...
... Provide Unprecedented Visibility into, Enterprise-Wide Spend Management Practices; Supplier Enablement Capability ... Spending with Preferred ... ... leader,in helping academic and research-centric organizations realize the,potential of strategic procurement, ...
... Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... clinical trial which is designed to support an ... for the treatment of patients,with NYHA Class II ... diligently on the ACCLAIM-II study,including the establishment of ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services 2AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services 3Vasogen Provides an Update on ACCLAIM-II Preparations 2Vasogen Provides an Update on ACCLAIM-II Preparations 3Vasogen Provides an Update on ACCLAIM-II Preparations 4
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... a common chemotherapy agent, researchers at UCLA's Jonsson Cancer ... found a way to move an important biomarker expressed ... in a cell ?where it could not be accessed ... The discovery, outlined in the cover article of May ...
... ended a decade-long controversy over the process by which ... ?the fragrant substances plants produce and which are often ... and other animals were incapable of making these substances. ... control pheromone production," said Gary Blomquist, professor and chair ...
... University of North Carolina at Chapel Hill's newest "library" ... book lover, but it eventually will please thousands of ... it will undoubtedly contribute to improving crops that humans ... say. , Named Phytome, the unique library is a ...
Cached Biology News:UCLA cancer researchers shake loose hidden biomarker 2Researchers discover key gene involved in bark beetle pheromone production 2Unique library of plant genes germinates, takes root at UNC 2
... Arabidopsis thaliana is the first higher plant ... serves as the primary model organism for ... content on this microarray is derived from ... for Genomic Research (TIGR) and from the ...
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
... its manganese-containing reaction buffer, converts long double-stranded ... (1825 bp) interfering RNAs (siRNA) suitable for ... (1 l) of ShortCut RNase III is ... into siRNA suitable for RNA interference in ...
...
Biology Products: